3rd Quarter 2023 Results[1]

Johnson&Johnson

3rd Quarter 2023 Sales

$21.4B Worldwide Increased ▲ **6.8%**

Excluding acquisitions/ divestitures on an operational basis: Worldwide Increased ▲ **4.9%***

Diluted Earnings Per Share

$1.69 | Increased ▲ **4.3%**

Adjusted Diluted Earnings Per Share*

$2.66 | Increased ▲ **19.3%**





"Johnson & Johnson delivered strong results and significant pipeline advances in the third quarter, providing a solid foundation for future sustained growth. With a sharpened focus on Innovative Medicine and MedTech solutions, Johnson & Johnson is innovating across the spectrum of healthcare and is poised to deliver the medical breakthroughs of tomorrow."

Joaquin Duato
Chairman of the Board & Chief Executive Officer
Johnson & Johnson

$13.9 Billion

Worldwide Innovative Medicine[2] Sales[3]

Innovative Medicine worldwide reported sales increased 8.9% or 8.2% operationally[4]. Primary operational drivers:

DARZALEX® (daratumumab) injection for intravenous infusion 100 mg/5 mL, 400 mg/20 mL
Stelara® (ustekinumab)
Tremfya® (guselkumab)
Erleada® (apalutamide) 60 mg tablets
CARVYKTI™ (ciltacabtagene autoleucel)
Simponi® golimumab
Spravato™ (esketamine) CII nasal spray

$7.5 Billion

Worldwide MedTech Sales

MedTech worldwide reported sales increased 10.0% or 10.4% operationally[4]. Primary operational drivers:

Abiomed
Electrophysiology
Wound Closure
Biosurgery
Contact Lenses
Surgical Vision
Hips
Knees
Trauma

Note: values may have been rounded.

For full financial data and non-GAAP reconciliations, please refer to Johnson & Johnson's earnings release issued on October 17, 2023, available at https://www.investor.jnj.com/financials/quarterly-results/default.aspx.

*Non-GAAP financial measure; non-GAAP financial measures should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures.

[1] Results have been recast to reflect the continuing operations of Johnson & Johnson.

[2] Previously referred to as Pharmaceutical.

[3] Excluding COVID-19 Vaccine.

[4] Non-GAAP measure; excludes the impact of translational currency.

Caution Concerning Forward-Looking Statements: This document contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding future operating and financial performance. You are cautioned not to rely on these forward-looking statements, which are based on current expectations of future events. For important information about the risks and uncertainties that could cause actual results to vary materially from the assumptions, expectations, and projections expressed in any forward-looking statements, review the "Note to Investors Concerning Forward-Looking Statements" included in the Johnson & Johnson earnings release issued on October 17, 2023, as well as the most recently filed Johnson & Johnson Reports on Forms 10-K and 10-Q. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.